Lung Cancer Treatment
Lung Cancer Treatment
No single therapy suits every lung cancer. This page compares the options that exist at each stage, what each one does to the tumor, and who each is right for — including patients told their tumor cannot be operated on.
How the right treatment is chosen
Four things decide it, and all four are known before any treatment starts:
Stage and location
A tumor confined to one lobe, a tumor touching the heart or airways, and a tumor that has spread to bone call for completely different approaches — even when the cells look identical under the microscope.
Molecular type
If the tumor carries an EGFR, ALK, ROS1, MET or RET alteration, an oral targeted drug is usually the better first choice than chemotherapy. If it does not, that option does not exist — which is why testing comes before treating.
Your lung function and fitness
The most effective treatment is only useful if your body can tolerate it. Preserving breathing capacity and independence is part of the goal, not a concession made afterwards.
Your own priorities
Two patients with the same scan can reasonably choose differently — one wanting the most aggressive option, another weighing time at home, work and quality of life. Both are legitimate, and both are part of the plan.
Treatment by stage, in plain terms
| Stage | Main treatment approaches | Cure or control |
|---|---|---|
| Stage I–II | Lung-sparing robotic surgery; breath-tracking radiosurgery (CyberKnife) when surgery is not suitable | Aim is cure |
| Stage III | Combined chemotherapy with radiation or immunotherapy, sometimes followed by surgery; radiosurgery for specific sites | Aim is cure or long-term control |
| Stage IV | Targeted therapy or immunotherapy when the molecular profile allows; chemotherapy; radiotherapy and interventional treatment for specific lesions | Aim is durable control and quality of life |
| Recurrence | Radiosurgery for isolated recurrences; re-testing for new mutations before choosing the next drug | Depends on pattern; often controllable |
Surgery: removing the cancer, keeping the lung
“If I need surgery, can you take only the cancer and leave the rest of my lung?”
Yes — that is the entire aim of modern lung surgery. Traditional operations removed more lung tissue than the cancer required, leaving permanent loss of breathing capacity. Robotic-assisted segmentectomy changes that: with a 10× magnified 3D view and fully wristed, tremor-free instruments, the surgeon dissects along exact anatomical planes, removing the diseased segment while preserving every unit of healthy lung and the vessels and airways that serve it.
The practical difference is measurable: less healthy tissue lost means more breathing capacity preserved for the rest of your life, smaller incisions, less post-operative pain and a faster return to normal activity. Radical does not have to mean excessive.
Breath-tracking radiosurgery: destroying early tumors without an operation
“The tumor moves every time I breathe. How do you hit it without harming my lung?”
That question is the whole engineering problem of lung radiosurgery. A lung tumor can move up to 2 cm with each breath. Older radiotherapy solved it by irradiating a wider area — which means more healthy lung, heart and spinal cord exposed to radiation. The CyberKnife M6 solves it differently: it follows the tumor in real time with 6D robotic positioning and delivers beams from 1,600+ angles with an accuracy of 0.1 mm, so no safety margin has to be added.
For early-stage or oligometastatic tumors, treatment is typically completed in 1–5 sessions as an outpatient — no incision, no anesthesia, no hospital stay. For patients who cannot have surgery, this is a genuine curative-intent alternative rather than a palliative compromise. And because the beams follow the tumor, lesions sitting near the heart, bronchi or spine can be treated that conventional radiotherapy could not reach safely.
Our network has completed ~1,000 CyberKnife treatments, and our teams have worked with lung-tracking technology for more than 25 years of continuous development.
Interventional and conversion therapy: when advanced does not mean finished
“I can't have surgery — or the tumor is too advanced. Is this the end?”
No — and “unresectable” is a snapshot, not a sentence. Interventional oncology treats tumors through a needle or a thin catheter, with no chest opening and no general anesthesia, in two complementary tracks.
Track one: physical destruction
Radiofrequency, microwave or cryoablation destroys tumor tissue with millimeter precision under imaging guidance. Iodine-125 seeds, each the size of a grain of rice, are implanted into involved lymph nodes or bone lesions and deliver continuous internal radiation for 60–180 days from a single procedure. Tumor hyperthermia heats the tumor to 40–43 °C, interfering with DNA repair and making the same dose of radiotherapy or chemotherapy more effective without adding toxicity.
Track two: conversion therapy
Superselective transarterial infusion uses a microcatheter to deliver chemotherapy directly into the artery feeding the tumor, achieving local drug concentrations 50–100× higher than intravenous administration while systemic side effects stay low. Drug-eluting embolization blocks the blood supply and releases drug locally at the same time — starving and poisoning the tumor in one procedure.
After 1–3 sessions, tumors often shrink substantially. For some patients this converts an inoperable cancer into an operable one; for others it makes the disease controllable without an operation at all.
Targeted therapy: matching the drug to the mutation
Targeted drugs block the specific molecular signal driving a tumor. They work only when that signal is present, which is why molecular testing comes first — see molecular profiling.
In East Asian patients, driver alterations in EGFR, ALK, ROS1, MET exon 14 skipping and RET fusions are relatively more common, particularly in people who have never smoked. For these patients, oral therapy can control the disease with fewer side effects than chemotherapy, and often allows normal daily life to continue.
“When my first targeted drug stops working, what comes next — and when?”
Resistance is expected rather than exceptional, and the real question is how quickly the next option becomes available. Later-generation EGFR inhibitors, newer ALK inhibitors, bispecific antibodies and China-origin combination regimens are often in routine clinical use here three to five years before other regions — guided by physicians who have managed these sequences in large numbers of patients, and re-tested at progression to identify the mechanism of resistance before choosing the next drug.
Immunotherapy: teaching the immune system to see the tumor
Immunotherapy removes the brakes that cancer cells use to hide from the immune system. It is most useful for tumors that express PD-L1, and it is increasingly given in combination with chemotherapy in first-line treatment for advanced disease, or after chemoradiotherapy in stage III disease.
The decision is never made on the immunotherapy result alone. PD-L1 expression, the presence or absence of driver mutations, overall fitness and any history of autoimmune disease all influence whether this route is right — because immunotherapy can help dramatically in some patients and add risk without benefit in others.
Chemotherapy and radiation: still essential, now more precise
Chemotherapy remains a cornerstone for small cell lung cancer and for non-small cell lung cancer without a targetable mutation, and it is combined with radiation in locally advanced disease where the goal is cure. Modern regimens are planned with anti-nausea support and dose adjustment to keep treatment tolerable.
Radiotherapy itself has changed: image guidance and stereotactic techniques similar to those used in radiosurgery now allow far more precise targeting than the broad-field radiation of even a decade ago, which means less exposure of the healthy lung, oesophagus and heart.
Integrative support: making treatment tolerable
Traditional Chinese medicine runs alongside mainstream treatment here, with two clearly defined goals rather than vague wellness claims:
Reducing toxicity
Herbal formulas support organ function, ease chemotherapy-related nausea and fatigue, and help limit bone-marrow suppression — with acupuncture for pain, nausea and fatigue management.
Supporting treatment delivery
The practical aim is completing planned treatment cycles on schedule. Delays caused by side effects are one of the most common reasons outcomes suffer — and one of the most fixable.
Clinical trial fast-track
When standard treatment options are exhausted, access to trials becomes the difference between waiting and treating. China runs one of the world's largest phase III oncology trial portfolios, and our teams can match you to trials based on NGS molecular profiling rather than tumor type alone.
Every enrollment is ethics-approved and takes place under full medical supervision. Trial therapies are typically available here three to five years before they reach routine use in other regions — which is why patients with rare mutations or after multiple lines of treatment often find options here that had been closed to them elsewhere.
If you are considering a trial, bring your molecular testing results and previous treatment history; those two documents determine what can be screened for.
When several options look reasonable, the decision should not be made by one department
Thoracic surgery, medical oncology, radiation oncology, interventional radiology, radiology and pathology review your case together and issue one unified recommendation — so that the answer is not shaped by which specialist you happened to see first. Upload your records and receive that plan within 48 hours.